Literature DB >> 25499154

The benefits of antiepileptic drug (AED) blood level monitoring to complement clinical management of people with epilepsy.

Daria Stepanova1, Roy G Beran2.   

Abstract

INTRODUCTION: Some argue that there is no evidence to support the use of antiepileptic drug (AED) blood level monitoring when treating people with epilepsy (PWE). This paper identifies how AED monitoring can be invaluable in such treatment. SPECIFIC EXAMPLES: (i) Compliance: Antiepileptic drug blood levels often confirm noncompliance rather than adequate seizure control, confirming subtherapeutic levels in PWE attending hospitals due to seizures. Routine monitoring of AED levels may prevent breakthrough seizures by identifying noncompliance and instituting heightened compliance measures before experiencing breakthrough seizures without modifying dosages. For PWE attending hospitals due to seizures, loading with the AED shown to be subtherapeutic may be all that is required. (ii) Cluster seizures and status epilepticus: When using long-acting AEDs to complement benzodiazepines, blood level monitoring confirms that an adequate dosage was given and, if not, a further bolus can be administered with further monitoring. This is particularly useful when using rectal administration of AEDs. (iii) Polypharmacy: Polypharmacy provokes drug interactions in which case AED monitoring helps in differentiating adequate dosing, offending AED with toxicity and free level measuring benefits when total levels are unhelpful. (iv) Generic substitution: Generic AEDs can fluctuate considerably from a parent compound, and even a parent compound, sourced from an alternative supplier, may have altered bioavailability for which blood level monitoring is very useful.
CONCLUSIONS: While therapeutic blood level monitoring is not a substitute for good clinical judgment, it offers a valuable adjunct to patient care.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AED blood levels; AED interactions; AED toxicity; Compliance; Generic substitution

Mesh:

Substances:

Year:  2014        PMID: 25499154     DOI: 10.1016/j.yebeh.2014.09.069

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  7 in total

1.  Clinical pharmacokinetics: perceptions of hospital pharmacists in Qatar about how it was taught and how it is applied.

Authors:  Nadir Kheir; Ahmed Awaisu; Hoda Gad; Shereen Elazzazy; Farah Jibril; Mawadda Gajam
Journal:  Int J Clin Pharm       Date:  2015-09-04

Review 2.  Levetiracetam Clinical Pharmacokinetic Monitoring in Pediatric Patients with Epilepsy.

Authors:  Jason Tan; Vanessa Paquette; Marc Levine; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2017-11       Impact factor: 6.447

3.  Pharmacokinetic characteristics of antiepileptic drugs (AEDs).

Authors:  Marketa Marvanova
Journal:  Ment Health Clin       Date:  2016-03-08

4.  Suboxone Treatment and Recovery Trial (STAR-T): Study Protocol for a Randomised Controlled Trial of Opioid Medication Assisted Treatment with Adjunctive Medication Management Using Therapeutic Drug Monitoring and Contingency Management.

Authors:  Hesham Elarabi; Abuelgasim Elrasheed; Ahmed Ali; Mansour Shawky; Nael Hasan; Tarek A Gawad; Abdu Adem; John Marsden
Journal:  J Addict       Date:  2019-03-05

5.  Prevalence of Non-adherence to Antiepileptic Drugs in Patients With Epilepsy Presenting to Emergency With Fits.

Authors:  Shakeel A Awan; Imran Khawaja; Muhammad Babar; Faheem Khan
Journal:  Cureus       Date:  2022-07-20

Review 6.  Clinical utility of therapeutic drug monitoring of antiepileptic drugs: Systematic review.

Authors:  Zanab Al-Roubaie; Elena Guadagno; Agnihotram V Ramanakumar; Afsheen Q Khan; Kenneth A Myers
Journal:  Neurol Clin Pract       Date:  2020-08

Review 7.  The critical interaction between valproate sodium and warfarin: case report and review.

Authors:  Chenguang Zhou; Yi Sui; Weijin Zhao; Chunyao Dong; Li Ren; Pingmei Song; Bing Xu; Xiaohong Sun
Journal:  BMC Pharmacol Toxicol       Date:  2018-10-01       Impact factor: 2.483

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.